Are Korean Biopharma Alliances Recovering After Gloomy Year?
Trend Toward Higher Upfronts
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
You may also be interested in...
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.
The two firms will co-develop and co-commercialize three Daiichi ADCs globally outside Japan in a deal the Japanese firm said would allow “more aggressive development plans targeting broader patient populations.”
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.